Concurrent follicular lymphoma and follicular dendritic cell sarcoma: composite neoplasm or transdifferentiation?

J HematopSep 26, 2026 (epub)
Case ReportOncology (Medical)Pathology (Anatomic & Clinical)Open access

Mahsa Hajizadeh, Jinbo Fan, Jeffrey W Craig et al.

✦ AI-curated · Sources linked

Case in brief

A 52-year-old woman presented with night sweats, weight loss, and an obstructing colonic mass with mesenteric disease. Biopsy revealed two distinct tumor populations: one consistent with follicular large B cell lymphoma and the other with follicular dendritic cell sarcoma. Genetic analysis showed shared BCL6 rearrangements and copy-number gains, raising questions about the relationship between the two neoplasms.

Diagnostic / clinical pearl

This case underscores the diagnostic complexity in differentiating between synchronous neoplasms and transdifferentiation, particularly when genetic alterations are shared.

Why it matters

Understanding the relationship between concurrent follicular lymphoma and follicular dendritic cell sarcoma can inform clinical management and future research into their pathogenesis.

Source

PubMed · PMID 42799816Free full text on PubMed Central

Published in J Hematop. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.